Please login to the form below
Incyte
Geron poleaxed as partner J&J abandons only pipeline drug
Analysts have suggested that might be a tough call given the increasingly competitive markets for MF and MDS, with firmly entrenched therapies such as Incyte and Novartis’Jakafi (ruxolitinib) and
J&J files ‘breakthrough’ bladder cancer drug in US
J&J could face near-term competition in the oral FGFR inhibitor category from Incyte, whose pemigatinib candidate is in phase 2 testing for bladder cancer and myeloid/lymphoid cancers, and ... Data from mid-stage studies should be available next year,
Cancer immunotherapy: What's on the horizon?
article – but, as recent experience with Incyte and Nektar Therapeutics has shown, not all new drugs and combinations will succeed. ... Meanwhile, Incyte’s Merck &Co partnered IDO inhibitor epacadostat bombed when paired with Keytruda in a melanoma
GSK sells eczema and psoriasis drug to Dermavant for £250m
s Xeljanz (tofacitinib), Incyte/Eli Lilly’s Olumiant (baricitinib) and AbbVie’s upadacitinib.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
- Events Manager – Med Comms – Surrey
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Director, Market Access / HEOR - North-West
-
Negotiable
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Director
-
Excellent benefits
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Associate Medical Director
-
Highly Competitive
- Senior Systematic Review Analyst - Oxford
-
Negotiable
-
Medical/ Scientific Director
-
Salary TBC
-
Senior Medical Writer
-
Competitive Salary
-
New Business Director - PR
-
Competitive Salary and benefits
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
-
Associate Director
-
£75, 000-90, 000
-
Account Manager / Account Director
-
Competative
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
Subscribe to our email news alerts
- Behaviour change – a missing ingredient?
- Animal Health Diagnostics Market Forecast Showing 9.53% CAGR to 2022
- Iron Drugs Market Set to Register 9.27% CAGR to 2022
- Medical Device Manufacturing Outsourcing Market to Soar at 11.92% CAGR to 2022
- Plaque Modification Devices Market Forecast Showing 8.19% CAGR to 2022
- Radiotherapy Market | Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2023
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
